A novel pharmacologic activity of ketorolac for therapeutic benefit in ovarian cancer patients

PURPOSE: We previously identified the R-enantiomer of ketorolac as an inhibitor of the Rho-family GTPases Rac1 and Cdc42. Rac1 and Cdc42 regulate cancer-relevant functions including cytoskeleton remodeling necessary for tumor cell adhesion and migration. This study investigated whether administratio...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Cancer Res
Huvudupphovsmän: Guo, Yuna, Kenney, S. Ray, Cook, Linda, Adams, Sarah F., Rutledge, Teresa, Romero, Elsa, Oprea, Tudor I., Sklar, Larry A., Bedrick, Edward, Wiggins, Charles L., Kang, Huining, Lomo, Lesley, Muller, Carolyn Y., Wandinger-Ness, Angela, Hudson, Laurie G.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4644688/
https://ncbi.nlm.nih.gov/pubmed/26071482
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0461
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk